Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1200148 | 0.81 | LIPG (0.44) | TAAR1GLACYP19A1CA2 | |
| SCHEMBL27922371 | 0.80 | CYP19A1 (0.38) | TAAR1CHRM3GLANPC1RAB9A | |
| SCHEMBL1134020 | 0.78 | TAAR1 (0.55) | TAAR1CNR1GLANPC1RAB9A | |
| SCHEMBL1133987 | 0.77 | LMNA (0.39) | CHRM3CHRM2KMT2ACHRM1PTGES | |
| SCHEMBL14857134 | 0.77 | CYP19A1 (0.39) | CHRM3NPC1RAB9ACYP19A1KMT2A | |
| SCHEMBL1199017 | 0.76 | CACNA1B (0.47) | NPC1RAB9ACYP19A1KMT2AMEN1 | |
| SCHEMBL14991463 | 0.75 | TPSAB1 (0.41) | CHRM3NPC1RAB9ACYP19A1KMT2A | |
| SCHEMBL1200134 | 0.75 | CHEK1 (0.54) | KMT2AMEN1 | |
| SCHEMBL1200268 | 0.75 | NPY1R (0.41) | CHRM3NPC1RAB9ACYP19A1 | |
| SCHEMBL13667957 | 0.73 | CHEK1 (0.31) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| WO-2009130475-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD., (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | IKBKE, CSNK1A1, CSNK1E | TAAR1 1648/4885CHRM3 1300/4885CNR1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.